Clinical Trial Detail

NCT ID NCT02638909
Title Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Criterium, Inc.
Indications

pancreatic adenocarcinoma

small intestine carcinoma

hepatocellular carcinoma

colorectal adenocarcinoma

esophagus adenocarcinoma

cholangiocarcinoma

gastric adenocarcinoma

Therapies

Ceritinib

Age Groups: adult

Additional content available in CKB BOOST